evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.
Company profile
Ticker
EOLS
Exchange
Website
CEO
David Moatazedi
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Evolus Pharma Limited • Evolus Pharma BV • Evolus International Ltd. • Evolus GmbH • Evolus Australia Pty Ltd ...
EOLS stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
13 Mar 24
424B5
Prospectus supplement for primary offering
11 Mar 24
S-8
Registration of securities for employees
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
7 Mar 24
8-K
Evolus Announces Preliminary Unaudited Fourth Quarter
16 Jan 24
8-K
Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
20 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Evolus Reports Record Third Quarter 2023 Financial Results
7 Nov 23
S-8
Registration of securities for employees
6 Oct 23
Transcripts
EOLS
Earnings call transcript
2023 Q4
7 Mar 24
EOLS
Earnings call transcript
2023 Q3
7 Nov 23
EOLS
Earnings call transcript
2023 Q2
2 Aug 23
EOLS
Earnings call transcript
2023 Q1
9 May 23
EOLS
Earnings call transcript
2022 Q4
8 Mar 23
EOLS
Earnings call transcript
2022 Q3
9 Nov 22
EOLS
Earnings call transcript
2022 Q2
2 Aug 22
EOLS
Earnings call transcript
2022 Q1
11 May 22
EOLS
Earnings call transcript
2021 Q4
4 Mar 22
EOLS
Earnings call transcript
2021 Q3
2 Nov 21
Latest ownership filings
4
Rui Avelar
21 Mar 24
4
Sandra Beaver
21 Mar 24
4
DAVID MOATAZEDI
21 Mar 24
4
DAVID MOATAZEDI
23 Feb 24
4
Rui Avelar
23 Feb 24
4
Sandra Beaver
23 Feb 24
SC 13G
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 38.69 mm | 38.69 mm | 38.69 mm | 38.69 mm | 38.69 mm | 38.69 mm |
Cash burn (monthly) | 1.01 mm | 2.24 mm | 5.63 mm | 5.24 mm | 308.00 k | 3.63 mm |
Cash used (since last report) | 5.99 mm | 13.33 mm | 33.52 mm | 31.19 mm | 1.83 mm | 21.62 mm |
Cash remaining | 32.69 mm | 25.35 mm | 5.16 mm | 7.50 mm | 36.85 mm | 17.07 mm |
Runway (months of cash) | 32.5 | 11.3 | 0.9 | 1.4 | 119.6 | 4.7 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 142 |
Opened positions | 20 |
Closed positions | 13 |
Increased positions | 61 |
Reduced positions | 31 |
13F shares | Current |
---|---|
Total value | 375.69 bn |
Total shares | 58.01 mm |
Total puts | 28.70 k |
Total calls | 467.20 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Medytox | 7.30 mm | $0.00 |
Stonepine Capital Management | 5.18 mm | $47.34 bn |
Flynn James E | 3.32 mm | $0.00 |
Daewoong Pharmaceutical | 3.14 mm | $39.81 mm |
Tang Capital Management | 3.10 mm | $28.31 bn |
Tang Capital Partners | 3.04 mm | $27.50 mm |
BLK Blackrock | 2.97 mm | $27.18 bn |
Vanguard | 2.70 mm | $24.67 bn |
First Manhattan | 2.29 mm | $20.91 bn |
Great Point Partners | 2.19 mm | $19.99 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Mar 24 | Moatazedi David | Common Stock | Sell | Dispose S | No | No | 13.9242 | 96,566 | 1.34 mm | 695,850 |
19 Mar 24 | Sandra Beaver | Common Stock | Sell | Dispose S | No | No | 13.9242 | 5,672 | 78.98 k | 154,201 |
19 Mar 24 | Avelar Rui | Common Stock | Sell | Dispose S | No | No | 13.9242 | 27,603 | 384.35 k | 372,288 |
22 Feb 24 | Moatazedi David | Common Stock | Sell | Dispose S | No | Yes | 13.0812 | 7,706 | 100.80 k | 792,416 |
22 Feb 24 | Avelar Rui | Common Stock | Sell | Dispose S | No | Yes | 13.0812 | 1,821 | 23.82 k | 399,891 |
21 Feb 24 | Moatazedi David | Common Stock | Grant | Acquire A | No | No | 0 | 61,202 | 0.00 | 800,122 |
21 Feb 24 | Avelar Rui | Common Stock | Grant | Acquire A | No | No | 0 | 13,115 | 0.00 | 401,712 |
News
12 Health Care Stocks Moving In Thursday's After-Market Session
21 Mar 24
Evolus Reports Pricing Of $50M Offering Of Common Stock
11 Mar 24
Stifel Reiterates Buy on Evolus, Raises Price Target to $25
8 Mar 24
Needham Reiterates Buy on Evolus, Maintains $22 Price Target
8 Mar 24
Mizuho Maintains Buy on Evolus, Raises Price Target to $23
8 Mar 24
Press releases
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
11 Mar 24
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8 Mar 24
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
7 Mar 24
Evolus Announces Results from European Head-to-Head Filler Trial
1 Mar 24
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
22 Feb 24